Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

被引：145

作者：

Shah, Nirav N. ^{[1
]}

Maatman, Theresa ^{[2
]}

Hari, Parameswaran ^{[1
]}

Johnson, Bryon ^{[1
]}

机构：

[1] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA

[2] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

CAR-T; antigen escape; B-cell NHL; B-cell ALL; immunotherapy; ANTIGEN ESCAPE; RECEPTOR; EFFICACY; RESISTANCE; LEUKEMIA;

D O I：

10.3389/fonc.2019.00146

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen on B cells durable remissions have been achieved in patients with B cell non-Hodgkin lymphoma and acute lymphoblastic lymphoma. Despite impressive responses, multiple escape mechanisms to evade CAR-T cell therapy have been identified, among which the most common is loss of the target antigen. In this review we will highlight outcomes to date with CD19 CAR-T cell therapy, describe the current limitations of single targeted CAR-T therapies, review identified tumor escape mechanisms, and lastly discuss novel strategies to overcome resistance via multi-targeted CAR-T cells.

引用

页数：7

共 50 条

[21] Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies [J].

Huang, Yuxian ;

Qin, Yinjie ;

He, Yingzhi ;

Qiu, Dezhi ;

Zheng, Yeqin ;

Wei, Jiayue ;

Zhang, Lenghe ;

Yang, Dong-Hua ;

Li, Yuhua .

DRUG RESISTANCE UPDATES, 2024, 74

[22] CAR T cell therapy for B-cell lymphomas [J].

Chavez, Julio C. ;

Locke, Frederick L. .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (02) :135-146

[23] CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma [J].

Su, Lihe ;

Wu, Lan ;

Lobb, Roy R. ;

Rennert, Paul D. ;

Ambrose, Christine .

ONCOIMMUNOLOGY, 2022, 11 (01)

[24] Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia [J].

Agrawal, Vaibhav ;

Murphy, Lindsey ;

Pourhassan, Hoda ;

Pullarkat, Vinod ;

Aldoss, Ibrahim .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (02) :236-247

[25] Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies [J].

Song, Moo-Kon ;

Park, Byeong-Bae ;

Uhm, Ji-Eun .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (20)

[26] Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T [J].

Crees, Zachary D. ;

Ghobadi, Armin .

CANCERS, 2021, 13 (20)

[27] Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies [J].

Wang, Hao ;

Kaur, Gurbakhash ;

Sankin, Alexander I. ;

Chen, Fuxiang ;

Guan, Fangxia ;

Zang, Xingxing .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)

[28] Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies [J].

Hao Wang ;

Gurbakhash Kaur ;

Alexander I. Sankin ;

Fuxiang Chen ;

Fangxia Guan ;

Xingxing Zang .

Journal of Hematology & Oncology, 12

[29] CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges [J].

Zhang, Xiaomin ;

Zhu, Lingling ;

Zhang, Hui ;

Chen, Shanshan ;

Xiao, Yang .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[30] Emerging Novel Combined CAR-T Cell Therapies [J].

Anh Nguyen ;

Johanning, Gary ;

Shi, Yihui .

CANCERS, 2022, 14 (06)

← 1 2 3 4 5 →